Live Updates S&P's Losing Streak, Mag 7 Correction3:29pm ETGerelyn TerzoThe markets remain under pressure as of mid-afternoon, with the exception of the Dow Jones Industrial Average, which is managing slight gains, thanks…
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO | NVO Price Prediction) was over. It said the Danish pharmaceutical had sufficient supply…
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. About This Article Just this morning, the US FDA said Novo…
Live Updates Quantum Leap3:39pm ETGerelyn TerzoStocks have managed to find their way into positive territory as of late afternoon. The Fed is looking for further inflation progress before moving rates, according to…
Stock markets got a bit of a shock on Friday after a University of Michigan survey showed consumers are anticipating inflation to rise in 2025, potentially depressing consumer spending and dissuading the…
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly (NYSE:LLY | LLY Price Prediction) has become the industry leader in a…
Live Updates Nasdaq Composite Off Its Daily Highs2:10pm ETEric BleekerThe Nasdaq Composite has fallen from its highs today but is still up about 1% as of 2:10 p.m. ET. Information Technology stocks…
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs…
Summer has officially begun, but some stocks are receiving a chilly reception today. Among them, Hims & Hers Health (NYSE: HIMS | AMZN Price Prediction), a telehealth and wellness platform, is down…
Gerelyn Terzo 
